News

COVID-19.info

Popularization of research advances on COVID-19

2021 - News Covid-19.info

4′-Fluorouridine: a promising oral antiviral

The COVID-19 pandemic has tragically revealed that we lack medicines against respiratory viral infections. Remdesivir is the only molecule to have been approved, but can only be administered intravenously. This limits its use to hospitalised patients and in general it is therefore given too late. Ideally, we need to have molecules that are effective against […]

Read more...

What happens to CD8+ memory cells a year after infection?

Since the beginning of the COVID-19 pandemic, biomedical research has tried to better understand long-term immunity against SARS-CoV-2. At the beginning of infection, T-CD8 cells proliferate, and activate as effector cells upon contact with viral antigens, to eventually eliminate infected cells from the body. In the case of COVID-19, we do not understand their evolution, […]

Read more...

The emergence of the virus and its propagation

At the end of 2019, the city of Wuhan reported cases of atypical pneumonia of unknown origin. Scientists then discovered that these cases were due to a new coronavirus, called SARS-CoV-2. The illness that resulted was named COVID-19, and it spread rapidly throughout the world, causing more than 5 million deaths in some 238 million […]

Read more...

Could the P681R mutation make Delta more pathogenic?

The enzyme involved in the SARS-CoV-2 genome mechanism of creating new virions makes random errors during this replication process, leading to mutations. When a mutation gives the virus an advantage, such as improved transmission effectiveness, it persists. The more a virus is transmitted, the more it reproduces, and the greater the risk of mutations. When […]

Read more...
Read more...

Profibrotic macrophages could lead to respiratory distress

Around 5% of COVID-19 patients develop Acute Respiratory Distress Syndrome (ARDS), the mechanisms of which are still poorly understood. The development of non- COVID-19 cases of ARDS has 3 stages: damage to the alveolar barrier and the appearance of pulmonary edema, proliferation of epithelial cells to restore this barrier and, in some patients, a phase […]

Read more...

Will the Omicron variant able to break through protection conferred by vaccines?

Even though the Delta (Indian) variant remains largely dominant in France, the first cases of the Omicron variant have already been detected. It has become dominant in South Africa and has reached numerous other countries. It carries multiple mutations, many more than other variants. Its spike viral protein, which enables entry of the virus into […]

Read more...

CoVac-1, a promising candidate vaccine

One of the solutions against the SARS-CoV-2 virus, which is responsible for COVID-19, is vaccines that are able to confer long-lasting immunity, especially in sectors of the population at high risk from complications. Currently available vaccines bring about a strong neutralising antibody response. But T lymphocytes also play an important role in antiviral defences by […]

Read more...

Does vaccine efficacy depend on antibody levels?

In the fight against the COVID-19 pandemic it is important to have a varied arsenal of safe and effective vaccines. Since global demand is high, prices must remain low enough to ensure equitable worldwide distribution. To complicate matters, we do not have data on vaccine efficacy for certain sectors of the population (pregnant women, children, […]

Read more...

The non-coding region of the mRNA of the Curevac vaccine has been optimised

Unlike other mRNA vaccines, the CVnCoV developed by CureVac does not use pseudouridine or nucleoside modification. The mRNA of the SARS-CoV-2 spike, which enables viral entry and is the main target of neutralising antibodies, is encapsulated in lipid nanoparticles in its stabilized pre-fusion form. Its efficacy has been evaluated in the HERALD (phase 2b/3) clinical […]

Read more...
error: Content is protected !!